
DocGo (DCGO) Stock Forecast & Price Target
DocGo (DCGO) Analyst Ratings
Bulls say
DocGo is supported by a deliberate shift toward higher-quality revenue, as management is exiting or restructuring about $60mm of unprofitable revenue and reducing costs to exit FY26 at a profitable run rate. Its core Mobile Health Services franchise remains the main engine, while Hicuity Health adds $65mm of TTM revenue, $4.5mm of adjusted EBITDA, and about $4.3mm of annual run-rate savings, strengthening the path to positive adjusted EBITDA in FY27. Although CEO turnover, higher leverage, and cash burn create execution risk, the combined platform’s cross-sell opportunity, broad hospital relationships, and stabilizing balance sheet make the long-term fundamental outlook attractive.
Bears say
DocGo is facing a weak fundamental setup because 3Q26 revenue of $73.4mm missed expectations, adjusted EBITDA was negative at ($3.2mm), and mobile health revenue fell 2.5% Y/Y to $20.2mm, showing that its core growth engine is under pressure. Management’s cut to FY26 revenue guidance to about $300mm from $305mm-$310mm, along with higher-than-expected legal, regulatory, and technology spending, signals execution problems and limited operating leverage despite 33.3% gross margins. The balance sheet and cash conversion remain key concerns as the company works through portfolio optimization, with roughly $24.3mm of cash, potential high-cost debt exposure, and a profitability path that still depends on timing-sensitive synergy realization and business-line restructuring.
This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.
DocGo (DCGO) Analyst Forecast & Price Prediction
Start investing in DocGo (DCGO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About DocGo (DCGO) Forecast
DocGo (DCGO) Analyst Forecast & Price Prediction
Start investing in DocGo (DCGO)
Order type
Buy in
Order amount
Est. shares
0 shares